Navigation Links
Labopharm reports results for Phase III study on twice-daily tramadol-acetaminophen formulation
Date:4/2/2009

y in clinical trials. Labopharm believes that it is likely that the results of this trial are insufficient to support the acceptance of a New Drug Application (NDA) by the Food and Drug Administration (FDA) in the United States. The Company intends to discuss the matter with the FDA's Division of Anesthesia, Analgesia & Rheumatology Products (DAARP) to determine the path forward. The results of this study are however statistically significant under analyses that the Company believes may be accepted for the evaluation of analgesics in Europe, Canada and other jurisdictions. Accordingly, the Company intends to meet with the regulatory authorities for these jurisdictions at the earliest available opportunity in pursuit of regulatory approval. Should the authorities be in agreement, the Company expects that it would submit a regulatory application in those jurisdictions.

The Company will provide additional information following discussions with the various regulatory authorities.

The results of the study have no bearing on the upcoming launch of the Company's once-daily tramadol product in the United States.

About Tramadol-Acetaminophen Combination Products

Tramadol-acetaminophen products leverage the unique but complementary modes of action of each of the active ingredients to provide the analgesic strength of a mild opioid (tramadol) and the rapid pain relief of acetaminophen. Tramadol-acetaminophen combination products were first launched in 2001 in the United States and in 2003 in other major markets and are indicated for the short-term (five days or less) management of acute pain in the U.S. and the symptomatic treatment of moderate to severe pain in the rest of the world.

About Labopharm Inc.

Labopharm is an emerging leader in optimizing the performance of existing small molecule drugs using its proprietary controlled-release technologies. The Company's lead product, a unique o
'/>"/>

SOURCE Labopharm Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Labopharm To Present Poster On Onset Of Analgesic Effect Of Once-Daily Tramadol At Congress Of The European Society Of Regional Anaesthesia And Pain Therapy
2. Labopharm provides update on U.S. regulatory process for once-daily Tramadol
3. Labopharm completes enrolment for Phase III clinical study for its once-daily trazodone antidepressant drug
4. Labopharm appeals FDAs decision on once-daily tramadol
5. Labopharm to host conference call Friday, November 9, 2007 at 8:30 a.m. (ET)
6. Labopharm to present at CIBC World Markets 18th Annual Healthcare Conference
7. Labopharm Reports Results for Third Quarter Fiscal 2007
8. Labopharm receives FDA response to appeal of Approvable Letter for once-daily tramadol
9. Labopharm enters into licensing and distribution agreement for once-daily tramadol in Australia with iNova
10. Canadian Marketing and Sales Effort for Labopharms Once-Daily Tramadol Product to Expand Significantly
11. Labopharm Reports Positive Results for Phase III Study on Once-daily Trazodone
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2015)... 2015 The report “Sinusitis ... analysis on the therapeutic development for Sinusitis. ... new targets and MOAs to produce first-in-class ... is available @ http://www.rnrmarketresearch.com/sinusitis-pipeline-review-h1-2015-market-report.html . ... involved in the therapeutic development for Sinusitis ...
(Date:4/21/2015)... Information is the best weapon in the fight ... patients and their families with knowledge about living with cancer ... is the Answer" and new website . , In ... patients from diagnosis through treatment and even death. The goal, ... treatment, at home and in the examination room. , “Cancer ...
(Date:4/21/2015)... 2015 Lyft has announced the ... otolaryngologists, bringing the most advanced speech-recognition technology to ... Otolaryngologists can now experience the full benefits of ... in the industry, Lyft, which offers value-added support ... , “Lyft is very excited to be able ...
(Date:4/21/2015)... On April 8th, 2015, Choices Recovery ... the world famous Avalon Hollywood. Organized by Debbie Durkin, ... TV and film, the EcoLuxe Lounge is a premier ... ceremonies and festivals throughout the year. A gathering of ... socially conscious products and services, this daylong event is ...
(Date:4/21/2015)... Colmar, PA (PRWEB) April 21, 2015 ... Ichthyosis & Related Skin Types, Inc.® (FIRST) will publish ... ichthyosis. The campaign will run throughout the month of ... Voice. It Matters to Someone." The positioning was ... about this rare skin disorder and to help support ...
Breaking Medicine News(10 mins):Health News:Sinusitis Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com 2Health News:Sinusitis Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com 3Health News:Authoritative guide and new accompanying therapeutic web portal bridge information gaps in cancer treatment 2Health News:Lyft Expands Its Offerings to Include Dragon® Medical Practice Edition 2 for Otolaryngologists. 2Health News:Hollywood's Santana Dempsey and Choices Recovery South Bend Examine Victory over Personal Struggles 2Health News:May is Ichthyosis Awareness Month. Use Your Voice. 2
... today announced,the release and first shipment of their marine-grade ... chair to oil and,gas platform operators in the Gulf ... platforms will enable the safe and timely evacuation of ... the dual-track MOV in response to the offshore,industry demands ...
... TAMPA, Fla., May 13 A complete review ... of a multi-disciplinary and,collaborative approach to weight loss, ... Clinics(R). The use of several proven,weight management strategies ... offer the greatest likelihood of success., NBC,s ...
... Performance during Sports or Play, CARLSBAD, Calif., May ... and retailer of custom-fitted arch supports and,natural sponge rubber ... of arch supports designed specifically for children ages 6 ... "SportFlex," are now,currently available at participating Good Feet Stores ...
... Israel, May 13 Lumenis Inc., a ... and radiofrequency,devices for surgical, aesthetic, and ophthalmic ... Laser Enucleation of the Prostate (HoLEP),preceptor program ... are interested in learning and performing HoLEP. ...
... 2008 Johnson & Johnson today announced that Professor ... Ravinder N. Maini, FRCP, FMedSci, FRS of the Kennedy ... the recipients of the 2008 Dr. Paul Janssen Award ... world-renowned scientists. , The award salutes the most ...
... Denmark, May 12, Warner Chilcott and LEO ... and Drug Administration (FDA) has approved the,New ... 0.005% and,betamethasone dipropionate 0.064%) Topical Suspension. LEO ... the FDA in July 2007. Taclonex Scalp(R) ...
Cached Medicine News:Health News:Research Converging in Favor of New Approach to U.S. Weight Problem 2Health News:Good Feet Announces New Arch Support Product Line for Children Ages 6 and Older 2Health News:Lumenis Launches HoLEP Preceptor Program at American Urology Association 2008 Annual Meeting 2Health News:Lumenis Launches HoLEP Preceptor Program at American Urology Association 2008 Annual Meeting 3Health News:Marc Feldmann and Sir Ravinder Maini win Dr. Paul Janssen Award for Biomedical Research 2Health News:Marc Feldmann and Sir Ravinder Maini win Dr. Paul Janssen Award for Biomedical Research 3Health News:FDA Approves Taclonex Scalp(R) - Once Daily Therapy for Treatment of Moderate to Severe Scalp Psoriasis 2Health News:FDA Approves Taclonex Scalp(R) - Once Daily Therapy for Treatment of Moderate to Severe Scalp Psoriasis 3Health News:FDA Approves Taclonex Scalp(R) - Once Daily Therapy for Treatment of Moderate to Severe Scalp Psoriasis 4
(Date:4/21/2015)... BROOK, N.Y. , April 21, 2015 /PRNewswire/ ... in health insurance marketplace integration and business operation, ... Entity (WBE) with the Centers of Medicare & ... establish an enrollment channel with access to the ... enrollment of eligible consumers into qualified health insurance ...
(Date:4/21/2015)... 2015 Seattle Children,s announced today that 20 ... trial using genetically reprogrammed T cells to treat relapsed ... by highly sensitive tests designed to detect minute amounts ... complete remission included children with very high tumor burdens ... as infants. "These results are extremely encouraging," ...
(Date:4/21/2015)... April 21, 2015 Legal cannabis ... to grow at a rapid pace over the next ... provide technology services for indoor/outdoor cultivators and new cannabis ... Surna Inc. (OTC: SRNA), Totally Hemp Crazy Inc. (OTC: ... (OTC: BVAP), 22 nd Century Group, Inc. (NYSE: ...
Breaking Medicine Technology:Softheon Confirms Web Broker Entity (WBE) Status with the Centers of Medicare & Medicaid Services (CMS) 2Seattle Children's Pediatric Leukemia Adoptive Therapy (PLAT-02) Clinical Trial Boasts 91% Complete Remission Rate in Children with Relapsed Leukemia 2Seattle Children's Pediatric Leukemia Adoptive Therapy (PLAT-02) Clinical Trial Boasts 91% Complete Remission Rate in Children with Relapsed Leukemia 3New Technology, Innovative Products & State-of-the-Art Equipment in the Legal Cannabidiol Industries Continue to Provide Growing Revenue Opportunities 2New Technology, Innovative Products & State-of-the-Art Equipment in the Legal Cannabidiol Industries Continue to Provide Growing Revenue Opportunities 3New Technology, Innovative Products & State-of-the-Art Equipment in the Legal Cannabidiol Industries Continue to Provide Growing Revenue Opportunities 4New Technology, Innovative Products & State-of-the-Art Equipment in the Legal Cannabidiol Industries Continue to Provide Growing Revenue Opportunities 5New Technology, Innovative Products & State-of-the-Art Equipment in the Legal Cannabidiol Industries Continue to Provide Growing Revenue Opportunities 6New Technology, Innovative Products & State-of-the-Art Equipment in the Legal Cannabidiol Industries Continue to Provide Growing Revenue Opportunities 7
... , , PRINCETON, N.J., Nov. 30 ... will present at the Piper Jaffray 21st Annual Health Care Conference ... may access a live webcast of the presentation at www.covance.com ... please log on 10 minutes early. , Covance, with headquarters in ...
... The Special Committee of Independent Directors of Patheon Inc. ("Patheon" ... its affiliate, JLL Patheon Holdings, LLC (collectively, "JLL"), today announced ... agreement in respect of the pending legal actions between the ... that: , until March 2011, the Board will consist ...
Cached Medicine Technology:Patheon and JLL Partners Announce Litigation Settlement 2Patheon and JLL Partners Announce Litigation Settlement 3
... optical collection, inspired by the ... Mademoiselle's heart, from the interlinked ... effect. Combining the purity of ... Strass and other light reflections, ...
... and sunwear, inspired by modern ... style, with long lasting wearability. ... collection include sophistication, elegance and ... clean modern shapes, classic styling ...
... frame mounting technology has redefined rimless collections ... taper at the end of each frame ... of the bushing that mounts within the ... a secure fit is created that far ...
... The new GUCCI DONNA eyewear collection ... house,incorporating, with a vintage yet contemporary feel, ... leader., The new GUCCI UOMO optical and ... is,presented in classic lines with cutting-edge design ...
Medicine Products: